Section 8: Clinical Vignettes

Vignette 1: The Bipolar II Patient Who "Needs" Her Antidepressant

Maria, a 34-year-old marketing director with bipolar II disorder, presents for medication management. She was diagnosed at age 28 after years of recurrent depression treated with sertraline. Her current regimen is lamotrigine 200 mg/day and sertraline 100 mg/day. She has been euthymic for 14 months.

Her psychiatrist recommends tapering the sertraline. Maria is terrified. "The last time someone took me off my antidepressant, I was back in bed within six weeks. I can't go through that again."

Clinical reasoning: Maria's fear is data-supported. The Altshuler et al. (2003) discontinuation data showed that 70% of patients who discontinued antidepressants within 6 months relapsed into depression, compared to 36% who continued (Section 3.3). However, the ISBD consensus framework also recognizes that maintenance antidepressants may be appropriate specifically when a patient has demonstrated relapse upon prior discontinuation (Section 3.6).

In Maria's case, several factors favor cautious continuation: she has bipolar II (lower switch risk than BD-I; Section 3.4), she is on an SSRI (lower-risk class; Section 3.5), she has mood stabilizer coverage (lamotrigine), she has documented prior relapse on discontinuation, and she has no history of antidepressant-induced mood elevation, rapid cycling, or mixed features. The ISBD framework permits maintenance antidepressant continuation in this specific clinical profile.

The clinical decision: continue the sertraline with close monitoring, educate Maria and her partner about early warning signs of mood elevation, and document the clinical rationale. This decision balances the Altshuler discontinuation data (which favors continuation for patients who have relapsed on discontinuation) against the Ghaemi meta-analytic finding that long-term maintenance antidepressants carry an NNH of 7 for manic induction versus NNT of 11 for depressive prevention (Section 3.2). In Maria's case, her bipolar II status (lower switch risk), her documented prior relapse on discontinuation, and her absence of risk factors (no mixed features, no rapid cycling, no prior TEAS) collectively favor continuation. This is an evidence-based decision to continue, not a reflexive one, and it should be revisited periodically.

For therapists: If you are seeing Maria for psychotherapy, your role includes monitoring for subtle signs of hypomania that she may not recognize (decreased sleep need without fatigue, increased goal-directed activity, uncharacteristic spending) and maintaining open communication with her prescriber.

Vignette 2: Choosing a First-Line Agent for Acute Bipolar I Depression

James, a 52-year-old electrician with bipolar I disorder, presents in a moderate-to-severe depressive episode (MADRS = 28). He has a BMI of 34, prediabetes (HbA1c 6.2%), and hypertension. He was previously stabilized on lithium 900 mg/day (level 0.7 mEq/L) but his current depressive episode has not responded to lithium optimization over 6 weeks. He has never had a trial of an atypical antipsychotic for depression.

Clinical reasoning: James needs the addition of a first-line agent for acute bipolar depression to his lithium base (Section 2). The treatment selection needs to account for his metabolic risk profile:

Quetiapine (NNT approximately 6) is the strongest acute option but its metabolic burden (NNH 16 for weight gain, NNH 3--4 for sedation; Section 2.2) makes it problematic in a patient with existing obesity, prediabetes, and hypertension. OFC is even more metabolically dangerous (NNH 6 for weight gain; Section 2.6) and is contraindicated here.

Lurasidone (NNT 5) offers comparable efficacy with metabolic neutrality (NNH 29 for weight gain at the lower dose range; weight gain was statistically indistinguishable from placebo at the higher dose range, making lurasidone effectively weight-neutral; Section 2.3). It requires administration with food (350+ calories). The primary risk is akathisia (17.7% incidence); James should be counseled about this and monitored with the BARS at follow-up. Cariprazine (NNT 10) is another metabolically favorable option, though with lower absolute efficacy. Lumateperone (NNT 15) offers the gentlest metabolic profile but lower absolute efficacy.

The evidence-based choice here is lurasidone added to lithium, initiated at 20 mg/day with food and titrated toward the 40--60 mg range based on response and tolerability (20 mg is the starting dose, not the target; the PREVAIL trials used 20--60 mg as a flexible dose range). This preserves lithium's maintenance and anti-suicidal benefits while adding a metabolically neutral antidepressant with strong acute evidence. If akathisia emerges, dose reduction or a switch to lumateperone would be appropriate next steps.

For all clinicians: James's metabolic monitoring (Section 4.4) should include baseline weight, BMI, fasting glucose/HbA1c, and lipid panel, repeated at weeks 4, 8, and 12, then quarterly. His prediabetes requires coordination with his primary care provider.

For therapists: If you are seeing James for psychotherapy during this medication transition, be aware that lurasidone can cause akathisia (inner restlessness, inability to sit still) in approximately 1 in 6 patients. In a therapy session, this may present as fidgeting, pacing, or difficulty engaging in seated conversation. It can be mistaken for anxiety or agitation from the depression itself. If you notice new-onset restlessness after James starts lurasidone, communicate this observation to the prescribing team; it may indicate akathisia rather than worsening mood, and the prescriber can adjust the dose or add a short-term intervention.

Vignette 3: Treatment-Resistant Bipolar Depression and the ECT Conversation

David, a 41-year-old teacher with bipolar I disorder, has been in a severe depressive episode for 9 months despite sequential adequate trials of quetiapine (600 mg/day, 10 weeks), lurasidone (120 mg/day, 8 weeks), and lithium-lamotrigine combination therapy. His MADRS is 32. He has passive suicidal ideation ("I think about not waking up") but no active plan. He has stopped going to work and his wife reports he has been nearly mute for the past two weeks.

Clinical reasoning: David meets the ISBD 2025 definition of treatment-resistant bipolar depression: failure of two or more adequate trials of approved agents at optimal dose and duration with verified adherence (Section 5.1). His near-mutism raises concern for catatonic features.

The evidence strongly supports ECT referral (Section 5.3). The Schoeyen trial showed ECT response rates of 73.9% versus 35.0% for continued pharmacotherapy in TRBD, with an NNT of approximately 2.6. Swedish registry data shows that response rates decline with each additional medication failure (Section 5.3), arguing against further cycling of oral medications. ECT also reduces suicide risk at 3-month follow-up (HR = 0.53) and all-cause mortality (HR = 0.70).

If David has catatonic features (mutism, rigidity, posturing), ECT becomes even more urgent, with response rates of 80.8% for catatonia (Section 5.4). An IV lorazepam challenge should be attempted first; if it fails, ECT is the definitive treatment.

The conversation with David and his wife should address common fears: modern ECT uses general anesthesia and muscle relaxants, cognitive side effects are typically transient and resolve within weeks, and the right unilateral ultrabrief pulse protocol used today substantially reduces memory effects compared to older bilateral techniques (Section 5.6). Practical logistics include the need for a driver during the treatment course and the typical schedule of 3 sessions per week for 3--4 weeks.

For therapists: If you are David's therapist, your role at this stage is to support the treatment team's recommendation, help David and his wife process fears about ECT, and provide continuity of care during and after the ECT course. You may be the first clinician to notice emerging catatonic features in session.

Key Takeaways for Clinical Practice

Bipolar depression is the dominant burden of the illness. Patients with bipolar I spend three times as many weeks depressed as manic; in bipolar II, the ratio approaches 37:1. Every bipolar treatment plan needs a specific strategy for the depressive phase, not just mania coverage (Judd et al., 2002, 2003).
The first-line agents for bipolar depression are not antidepressants. Quetiapine, lurasidone, lamotrigine, lithium, cariprazine, and lumateperone are the evidence-based first-line options. Treatment selection should be individualized based on efficacy needs, metabolic risk, and side-effect profile using the NNT/NNH framework.
Lurasidone and lumateperone offer efficacy with metabolic neutrality. For patients with metabolic risk factors (obesity, prediabetes, metabolic syndrome), these agents provide strong or moderate antidepressant efficacy without the weight gain, dyslipidemia, and sedation burden of quetiapine or OFC.
Antidepressants are a third-line option, not a first response. The STEP-BD trial showed no benefit of adjunctive antidepressants over mood stabilizer plus placebo. If antidepressants are used, they should follow first- and second-line failures, always with mood stabilizer coverage, and never in the presence of mixed features, rapid cycling, or prior antidepressant-induced switch. Prefer SSRIs or bupropion; avoid TCAs and SNRIs.
Lithium remains the strongest maintenance agent and the only psychiatric medication with a consistent signal for suicide risk reduction. An NNT of 5 for relapse prevention over one year, and a protective signal for completed suicide (OR = 0.13 in the Cipriani 2013 meta-analysis, though subsequent larger meta-analyses have yielded wider confidence intervals that did not reach significance), are among the most favorable efficacy metrics in psychiatry. Lithium should be considered for every patient with significant suicide risk.
Valproate monotherapy is inferior to lithium for maintenance. The BALANCE trial demonstrated that valproate alone was inferior to both lithium alone and the lithium-valproate combination. Patients on valproate monotherapy who relapse should be augmented with or transitioned to lithium.
Lamotrigine fills the depressive gap that lithium leaves. Lithium primarily prevents manic relapse; lamotrigine primarily prevents depressive relapse. Combined, they provide complementary polarity coverage. Lamotrigine's favorable tolerability profile makes it a cornerstone of long-term maintenance.
For prescribers: Recognize treatment-resistant bipolar depression early and refer for ECT before deep resistance develops. ECT response rates decline from 82% in treatment-naive patients to 63% after five or more medication failures. Earlier referral produces better outcomes.
For therapists: Sleep and circadian rhythm monitoring is a form of treatment. IPSRT is the only psychotherapy specifically designed for bipolar disorder’s chronobiological vulnerability. Even without formal IPSRT certification, tracking sleep-wake regularity and communicating disruptions to the prescribing team adds substantial clinical value. In the STEP-BD trial, the overall NNT for intensive psychotherapy versus standard care was approximately 8 (64.4% vs. 51.5% recovery), with a dramatically stronger effect in the most recurrently ill subgroup: for patients with 10--20 prior depressive episodes, the NNT was approximately 2.0 (Miklowitz et al., 2007).
For all clinicians: A sudden decrease in sleep need is the most reliable early warning sign of emerging mania and should prompt immediate clinical contact, medication review, and assessment of the current treatment regimen.
For school psychologists: Recognize how bipolar medications affect classroom functioning. Quetiapine commonly causes daytime sedation that may look like disengagement or low motivation. Akathisia from lurasidone or cariprazine can present as fidgeting, inability to stay seated, or restlessness that mimics ADHD. Significant weight gain from olanzapine or quetiapine may affect self-esteem and peer relationships. When you observe these patterns in a student with bipolar disorder, communicate with the treatment team; what looks like a behavioral issue may be a medication side effect that the prescriber can address.

Key References

Starred (★) papers are recommended for clinicians who want to read further.

**★ **Judd, L. L., Akiskal, H. S., Schettler, P. J., et al. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry, 59(6), 530--537.

**★ **Judd, L. L., Akiskal, H. S., Schettler, P. J., et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry, 60(3), 261--269.

**★ **Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine, 356(17), 1711--1722.

**★ **Altshuler, L. L., Post, R. M., Leverich, G. S., et al. (2003). Relapse into depression following discontinuation of antidepressants in bipolar depression. American Journal of Psychiatry, 160(7), 1252--1262.

**★ **Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., et al. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry, 170(11), 1249--1262.

**★ **Geddes, J. R., Burgess, S., Hawton, K., et al. (2004). Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry, 161(2), 217--222.

**★ **Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ, 346, f3646.

**★ **Geddes, J. R., Goodwin, G. M., Rendell, J., et al. (2010). Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. The Lancet, 375(9712), 385--395.

Keramatian, K., Chakrabarty, T., Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: summary and a 2023 update of evidence. Focus, 21(4), 344--353.

Citrome, L. (2014). Treatment of bipolar depression: making sensible decisions. Journal of Clinical Psychiatry, 75(Suppl 1), 15--20.

**★ **Calabrese, J. R., Huffman, R. F., White, R. L., et al. (2008). Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disorders, 10(2), 323--333.

Calabrese, J. R., Bowden, C. L., Sachs, G., et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry, 64(9), 1013--1024.

Bowden, C. L., Calabrese, J. R., Sachs, G., et al. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry, 60(4), 392--400.

Miura, T., Noma, H., Furukawa, T. A., et al. (2014). Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. The Lancet Psychiatry, 1(5), 351--359.

Bowden, C. L., Calabrese, J. R., McElroy, S. L., et al. (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Archives of General Psychiatry, 57(5), 481--489.

Loebel, A., Cucchiaro, J., Silva, R., et al. (2014). Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. American Journal of Psychiatry, 171(2), 160--168.

Schoeyen, H. K., Kessler, U., Andreassen, O. A., et al. (2015). Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. American Journal of Psychiatry, 172(1), 41--51.

**★ **Frank, E., Kupfer, D. J., Thase, M. E., et al. (2005). Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Archives of General Psychiatry, 62(9), 996--1004.

**★ **Miklowitz, D. J., Otto, M. W., Frank, E., et al. (2007). Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Archives of General Psychiatry, 64(4), 419--426.

Calabrese, J. R., Sanchez, R., Jin, N., et al. (2017). Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. Journal of Clinical Psychiatry, 78(3), 324--331.

Harlin, M., Abell, M., Baker, R., et al. (2023). Aripiprazole 2-month ready-to-use (Ari 2MRTU 960 mg): pharmacokinetics, safety, and tolerability. CNS Drugs, 37, 443--456.

Henriksen, T. E., Skrede, S., Fasmer, O. B., et al. (2016). Blue-blocking glasses as additive treatment for mania: a randomized placebo-controlled trial. Bipolar Disorders, 18(3), 221--232.

Rakofsky, J. J., Lucido, M. J., & Dunlop, B. W. (2022). Lithium in the treatment of acute bipolar depression: a systematic review and meta-analysis. Journal of Affective Disorders, 308, 53--62.

Earley, W., Burgess, M. V., Rekeda, L., et al. (2019). Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. American Journal of Psychiatry, 176(6), 439--448.

Dorz, S., Borgherini, G., Conforti, D., et al. (2003). Comparison of self-rated and clinician-rated measures of depressive symptoms in unipolar and bipolar patients. Journal of Affective Disorders, 76(1--3), 267--271.

D'Agostino, A., Fagiolini, A., Benedetti, F., et al. (2020). Chronotherapy for bipolar depression: a systematic review. Journal of Affective Disorders, 264, 285--295.

Goldberg, J. F., Perlis, R. H., Bowden, C. L., et al. (2007). Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. American Journal of Psychiatry, 164(11), 1766--1774.

Kadakia, A., Dembek, C., Heller, V., et al. (2021). Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry, 21(1), 249.

Kishi, T., Oya, K., & Iwata, N. (2016). Long-acting injectable antipsychotics for the prevention of relapse in bipolar disorder: a systematic review and meta-analyses. International Journal of Neuropsychopharmacology, 19(9), pyw038.

van der Loos, M. L., Mulder, P. G., Hartong, E. G., et al. (2011). Adjunctive lamotrigine for treatment-resistant bipolar depression. American Journal of Psychiatry, 168(4), 431--440.

Medda, P., Toni, C., & Perugi, G. (2015). The mood-stabilizing effects of electroconvulsive therapy. Journal of ECT, 31(2), 68--72.

Kishi, T., Ikuta, T., Sakuma, K., et al. (2019). Melatonin receptor agonists (ramelteon and melatonin) for bipolar disorder. Neuropsychiatric Disease and Treatment, 15, 1479--1486.

Yatham, L. N., Kennedy, S. H., Parikh, S. V., et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97--170.

Keck, P. E., Calabrese, J. R., McIntyre, R. S., et al. (2007). Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. Journal of Clinical Psychiatry, 68(10), 1480--1491.

Ghaemi, S. N., Wingo, A. P., Filkowski, M. A., & Baldessarini, R. J. (2008). Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatrica Scandinavica, 118(5), 347--356.

McGirr, A., Vöhringer, P. A., Ghaemi, S. N., Lam, R. W., & Yatham, L. N. (2016). Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. The Lancet Psychiatry, 3(12), 1138--1146.

Nierenberg, A. A., et al. (2025). Defining treatment-resistant bipolar depression: new recommendations from the ISBD Task Force. Bipolar Disorders, 27(4), 289--301.

De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology, 8(2), 114--126.

Baldessarini, R. J., Leahy, L., Arcona, S., Gause, D., Zhang, W., & Hennen, J. (2007). Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Services, 58(1), 85--91.

Savitz, J. B., Nugent, A. C., Bogers, W., et al. (2011). Habenula volume in bipolar disorder and major depressive disorder. Biological Psychiatry, 69(7), 658--665.

Semkovska, M., & McLoughlin, D. M. (2010). Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biological Psychiatry, 68(6), 568--577.

Tondo, L., Vázquez, G., & Baldessarini, R. J. (2010). Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatrica Scandinavica, 121(6), 404--414.

Geddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009). Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry, 194(1), 4--9.

Bahji, A., Hawken, E. R., Sepehry, A. A., Cabrera, C. A., & Vazquez, G. (2019). ECT beyond unipolar major depression: systematic review and meta-analysis of electroconvulsive therapy in bipolar depression. Acta Psychiatrica Scandinavica, 139(3), 214--226.

Brown, E. B., McElroy, S. L., Keck, P. E., et al. (2006). A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. International Journal of Neuropsychopharmacology, 9(5), 617--623.

Calabrese, J. R., Keck, P. E., Macfadden, W., et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry, 162(7), 1351--1360.

Citrome, L. (2011). Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International Journal of Clinical Practice, 65(2), 189--210.

Citrome, L. (2013). Lurasidone in the treatment of bipolar depression: evidence from clinical studies. Expert Opinion on Pharmacotherapy, 14(15), 2047--2067.

PsychHQ

Clinical Vignettes & Key Takeaways